Abstract:Summary objective: To assess the clinical features and outcomes of hematological disease patients with Candida tropicalis bloodstream infections and determine the antifungal susceptibility of C. tropicalis . Methods: This is a retrospective, single-center, observational study conducted in the Department of Hematology at The First Affiliated Hospital of Guangxi Medical University from January 2013 to December 2021. A total of 26 hematological disease patients with C. tropicalis bloodstream infections were enrolled, and their clinical features, treatment plans, and prognoses were assessed. Univariate analysis was performed by Kaplan–Meier analysis and multivariate analysis was conducted using a Cox regression model. The antifungal susceptibility of C. tropicalis was determined from patient blood cultures. Results: The patients had a mean age of 35 years (range: 10–65 years), 50% were male (13/26) and 88.5% had hematologic malignancies (23/26) while the remaining three patients included two cases of severe aplastic anemia and one case of β-thalassemia. All patients had neutropenia. Seven patients were initially given azole alone (26.9%), five of whom failed treatment and died (71.4%). Fifteen patients were treated with echinocandin (57.7%), three of whom failed treatment and died (20.0%), and eight patients were treated with amphotericin B (30.8%), two of whom failed treatment and died (25.0%). The total and attributable mortality rates were 42.3 and 34.6%, respectively. Univariate analysis showed that there are six risk factors for attributable deaths among hematological disease patients with C. tropicalis blood infections. These risk factors included septic shock, Pitt bacteremia scores ≥4, procalcitonin levels ≥10 ng/mL, positive plasma (1,3)- β-D glucan assay, serum albumin levels <30.0 g/L, time from fever to antifungal treatment initiation ≥5 days and time between neutropenia and antifungal treatment ≥10 days. Moreover, skin and mucosal infections and a treatment schedule that included amphotericin B and drug combinations are protective factors for attributable deaths. Multivariate analysis showed that septic shock ( p = 0.006) was an independent risk factor for attributable death. All isolates were sensitive to flucytosine and amphotericin B. The intermediate or resistance of C. tropicalis to fluconazole, itraconazole and voriconazole were 41.7, 50, and 41.7%, respectively. Conclusion: Hematological disease patients with C. tropicalis bloodstream infections had a high mortality rate, and early antifungal therapy significantly reduced mortality. Candida tropicalis was highly resistant to azole drugs and sensitive to flucytosine and amphotericin B. According to our study, the preferred agent is amphotericin B and drug combinations should be considered for severe infections.

Risk Factors for Candida tropicalis Fungemia in Patients with Cancer

Clinical analysis of 14 cases of candidemia

Successful treatment of Candida tropicalis osteomyelitis with Micafungin in a leukemia patient

Candidemia Tropicalis in Acute Leukemia Patients:Clinical Characteristics and Risks Factors

The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer

Risk Factors and Prognostic Analysis of Candida Tropicalis Fungemia in Patients with Different Immune Function

Clinical Features, Strain Distribution, Antifungal Resistance and Prognosis of Patients with Non-albicans Candidemia: A Retrospective Observational Study.

A clinical analysis of Candida tropicalis bloodstream infections associated with hematological diseases, and antifungal susceptibility: a retrospective survey

Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy

Multiple‐species candidemia in patients with cancer

Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome

The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy

Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome

[Candida Colonization and Invasive Fungal Infection in Hospitalized Patients with Hematological Malignancies].

The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality

Drug-resistant Candida glabrata infection in cancer patients

Breakthrough candidemia in patients with cancer differs from de novo candidemia in host factors and Candida species but not intensity

Poor prognosis of Candida tropicalis among non-albicans candidemia: A retrospective multi-center cohort study, Korea

Candida tropicalis-A systematic review to inform the World Health Organization of a fungal priority pathogens list

Uncommon Candida species fungemia among cancer patients, Houston, Texas, USA

Clinical Features and Prognostic Risk Factors of Candidemia in Non-Intensive Care Unit Wards